Therefore, NF-κB inhibitors, namely these targeting the IKK protein family, have shown great potential for treating inflammatory diseases and bone diseases that are associated with impaired bone-remodeling processes such as rheumatoid arthritis and inflammatory osteolysis20–22. Here, NFKB1 is linked to rheumatoid arthritis.